Table of Contents Table of Contents
Previous Page  801 / 1631 Next Page
Information
Show Menu
Previous Page 801 / 1631 Next Page
Page Background

• CMT has been the standard (with CHOP)

• Recent changes:

– Rituximab

improved PFS & OS

– PET

response assessment

– Omitting RT in HL

• Need to revaluate role of RT in DLBCL